Gene Therapy Treats Sickle Cell Disease in Teenager Using Lentiviral Vector – Medscape
Medscape |
Gene Therapy Treats Sickle Cell Disease in Teenager Using Lentiviral Vector
Medscape Gene therapy that delivered an antisickling variant of hemoglobin in an autologous hematopoietic stem cell (HSC) transplant has ameliorated symptoms of severe sickle cell disease (SCD) in a 15-year-old boy, according to a report published in the March … Gene therapy lets a French teen dodge sickle cell diseaseThe Seattle Times Gene Therapy: A Breakthrough for Sickle Cell Anemia?Lincoln Journal Star One boy’s cure raises hopes and questions about gene therapy for sickle cell diseaseSTAT |
Seymour Tribune |
Gene therapy lets a French teen dodge sickle cell disease
Seymour Tribune A French teen who was given gene therapy for sickle cell disease more than two years ago now has enough properly working red blood cells to dodge the effects of the disorder, researchers report. The first-in-the-world case is detailed in Thursday’s New … |
The Seattle Times |
Gene therapy lets a French teen dodge sickle cell disease
The Seattle Times Researchers say a French teen who was given gene therapy for sickle cell disease more than two years ago now has enough properly working red blood cells to dodge the effects of the disorder. The case is detailed in the March 2, 2017 issue of the New … Gene Therapy Treats Sickle Cell Disease in Teenager Using Lentiviral VectorMedscape Gene therapy ‘cures’ boy of blood disease that affects millionsNew Scientist Gene Therapy: A Breakthrough for Sickle Cell Anemia?HealthDay STAT all 9 news articles » |
|
ALK announces FDA approval for its house dust mite sublingual allergy immunotherapy tablet (ACARIZAX® in Europe)
GlobeNewswire (press release) ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet. The HDM … |
|
ALK announces FDA approval for its house dust mite sublingual allergy immunotherapy tablet (ACARIZAX® in Europe)
GlobeNewswire (press release) ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet. The HDM … |
New Scientist |
Gene therapy ‘cures’ boy of blood disease that affects millions
New Scientist The idea of gene therapy – using strands of DNA to compensate for a person’s malfunctioning genes – is almost three decades old. However, the approach has so far mostly been used to treat very rare diseases (see “Long road to success“). In contrast … Gene Therapy: A Breakthrough for Sickle Cell Anemia?Lincoln Journal Star Gene Therapy Treats Sickle Cell Disease in Teenager Using Lentiviral VectorMedscape One boy’s cure raises hopes and questions about gene therapy for sickle cell diseaseSTAT MedPage Today all 9 news articles » |
Futurism |
A New Cancer Treatment Has Given Terminal Patients a Second Chance at Life
Futurism Gene therapy has been shown in clinical trials to not just treat cancer, but possibly cure it. The treatments have risks — including death — so additional research is needed before they could become widely available. |
Xconomy |
After Trial Deaths, Juno Pivots and Scraps Lead CAR–T Therapy
Xconomy Juno Therapeutics said today it would discontinue its experimental CAR–T cell product known as JCAR015. It was once Juno’s top candidate as the company raced rivals to be the first to win approval of a new kind of cancer treatment called CAR-T. The … |